Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
In today's Pharmaceutical Executive Daily, we cover the FDA approval of Bayer's Lynkuet for menopausal hot flashes and Novartis' $12 billion merger agreement to acquire Avidity Biosciences.
- The FDA has approved Bayer's Lynkuet, also known as elinzanetant, for the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Lynkuet provides a non-hormonal option for patients seeking relief from menopausal symptoms without estrogen exposure.
New research suggesting Ozempic may reduce biological age.
Author's summary: Ozempic may reduce biological age according to new research.
More News
- The United States Is Broke. Americans May Not Care - But the World Does - The Heartland Institute
- Offshore wind projects feel brunt of Trump policy decisions - Roll Call
- Nicole Kidman thriving while Keith Urban struggles after split
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- LIVE: Road blocked after serious crash
- The Angel Ball Honors Tina Knowles
- Nag: Dam! What happened to the salmon? - Daily Emerald
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary